CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 19, 2013--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer by the targeted killing of cancer stem cells,
today announced that it has been selected for addition to the NASDAQ
Biotechnology Index (NASDAQ:NBI). The addition to the NASDAQ
Biotechnology Index will become effective upon market open on December
The NASDAQ Biotechnology Index is designed to track the performance of a
set of NASDAQ-listed securities that are classified as either
biotechnology or pharmaceutical according to the Industry Classification
Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. The
NASDAQ Biotechnology Index is the basis for the iShares NASDAQ
Biotechnology Index Fund (NASDAQ:IBB), which seeks investment results
that correspond generally to the price and yield performance, before
fees and expenses, of the NASDAQ Biotechnology Index. In addition,
options based on the iShares NASDAQ Biotechnology Index Fund trade on
various exchanges. For more information about the NASDAQ Biotechnology
Index visit www.nasdaq.com.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to
treat cancer by the targeted killing of cancer stem cells. Cancer stem
cells are an underlying cause of tumor recurrence and metastasis.
Verastem is developing small molecule inhibitors of signaling pathways
that are critical to cancer stem cell survival and proliferation: FAK,
PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.
Any statements in this press release about future expectations, plans
and prospects for the Company constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements. The Company anticipates that subsequent
events and developments will cause the Company’s views to change.
However, while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Source: Verastem, Inc.
Brian Sullivan, 617-252-9314